Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
152
datasets available to search
ShareScore release 0.9.0
Dataset results
152 results for “Polyneuropathy”
An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy
ClinicalTrials.gov study NCT00791492. IPD Sharing: Not stated. Countries: 6. Publications: 5.
Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy
ClinicalTrials.gov study NCT00278629. IPD Sharing: NO. Countries: 1. Publications: 1.
Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
ClinicalTrials.gov study NCT00220740. IPD Sharing: Not stated. Countries: 10. Publications: 7.
Peripheral Magnetic Stimulation With Balance Training to Decrease Fall Risks in Diabetic Polyneuropathy
ClinicalTrials.gov study NCT07000214. IPD Sharing: YES. Countries: 0. Publications: 9.
Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy
ClinicalTrials.gov study NCT01737398. IPD Sharing: NO. Countries: 10. Publications: 11.
Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
ClinicalTrials.gov study NCT01184846. IPD Sharing: Not stated. Countries: 5. Publications: 2.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
ClinicalTrials.gov study NCT01545076. IPD Sharing: Not stated. Countries: 16. Publications: 2.
Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)
ClinicalTrials.gov study NCT02175004. IPD Sharing: Not stated. Countries: 9. Publications: 4.
Effect of Exercise and Surgical Weight Loss on Polyneuropathy
ClinicalTrials.gov study NCT03617185. IPD Sharing: NO. Countries: 1. Publications: 1.
Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
ClinicalTrials.gov study NCT04658472. IPD Sharing: YES. Countries: 10. Publications: 1.
A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the
ClinicalTrials.gov study NCT04281472. IPD Sharing: UNDECIDED. Countries: 25. Publications: 1.
Pain in patients with Type 2 diabetes-related polyneuropathy is associated with vascular events and mortality
<p>Type 2 diabetes–related polyneuropathy (DPN) is associated with increased vascular events and mortality, but determinants and outcomes of pain in DPN are poorly understood. We sought to examine the effect of neuropathic pain on vascular events and mortality in patients without DPN, DPN with pain (DPN + P), and DPN without pain (DPN-P). A retrospective cohort study was conducted within a large health system of adult patients with type 2 diabetes from January 1, 2009 through December 31, 2016. Using an electronic algorithm, patients were classified as no DPN, DPN + P, or DPN-P. Primary outcomes included number of vascular events and time to mortality. Independent associations with DPN + P were evaluated using multivariable negative binomial and Cox proportional hazards regression models, adjusting for demographics, socioeconomic characteristics, and comorbidities. Of 43 945 patients with type 2 diabetes (age 64.6 ± 14.0 years; 52.1% female), 13 910 (31.7%) had DPN: 9104 DPN + P (65.4%) vs 4806 DPN-P (34.6%). Vascular events occurred in 4538 (15.1%) of no DPN patients, 2401 (26.4%) DPN + P, and 1006 (20.9%) DPN-P. After adjustment, DPN + P remained a significant predictor of number of vascular events (incidence rate ratio [IRR] = 1.55, 95% CI, 1.29-1.85), whereas no DPN was protective (IRR = 0.70, 95% CI, 0.60-0.82), as compared to DPN-P. Compared to DPN-P, DPN + P was also a significant predictor of mortality (hazard ratio = 1.42, 95% CI, 1.25-1.61). Our study found a significant association between pain in DPN and an increased risk of vascular events and mortality. This observation warrants longitudinal study of the risk factors and natural history of pain in DPN.</p> <p> </p>
Data from: Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy
Objectives: To assess natural history and treatment effect on survival among transthyretin-associated familial amyloid polyneuropathy (TTR-FAP) Val30Met patients. Methods: Multi-institutional, hospital-based study of TTR-FAP Val30Met patients prospectively followed-up until December 2016, grouped into untreated (n = 1,771), liver transplant (LTx) (n = 957) or tafamidis-treated (n = 432) cohorts. Standardized mortality ratios (SMR), Kaplan-Meier and Cox methods were used to estimate excess mortality, survival probabilities and adjusted hazard ratios (HR) for all-cause mortality, respectively. Results: Disease-modifying treatments decreased TTR-FAP excess mortality from ten to four (SMR 3.92, 95% CI 2.64–5.59). Median overall survival of untreated and LTx-treated cohorts was 11.61 (95% CI 11.14–11.87) and 24.73 years (95% CI 22.90-27.09), respectively, and was not reached in the tafamidis-treated cohort (maximum follow-up, 10 years). Both disease-modifying treatments improved survival. Among early-onset patients (<50 years of age) tafamidis reduced the mortality risk compared with untreated patients by 91% (HR 0.09, 95% CI 0.03–0.25, p < 0.001) and with LTx-treated patients by 63% (HR 0.37, 95% CI 0.14–1.00, p = 0.050). Previous tafamidis treatment did not affect mortality risk after LTx (HR 0.83, 95% CI 0.25-2.78, p = 0.763). Among late-onset patients (≥50 years), tafamidis reduced mortality risk by 82% compared with untreated patients (HR 0.18, 95% CI 0.06-0.49, p = 0.001). Conclusions: LTx and tafamidis convey substantial survival benefits, but TTR-FAP mortality remains higher than in the general population. These results strongly reinforce the importance of timely diagnosis and earlier treatment, boosting the pursuit for an increased life expectancy.
Effect of Non-invasive Vagus Nerve Stimulation on Cognitive Functions in Diabetic Polyneuropathy Patients
ClinicalTrials.gov study NCT06048653. IPD Sharing: NO. Countries: 1. Publications: 3.
Impact Of Sensory Re-Education Paradigm On Sensation And Quality Of Life In Patients Post-Covid 19 Polyneuropathy
ClinicalTrials.gov study NCT05911113. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Statins for Oxidative Stress and Mitochondrial Function in Diabetic Polyneuropathy
ClinicalTrials.gov study NCT02129231. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Phase IV Trial to Evaluate Efficacy of Alpha-Lipoic Acid in Treating Symptomatic Diabetic Polyneuropathy in Egypt
ClinicalTrials.gov study NCT05813496. IPD Sharing: NO. Countries: 1. Publications: 5.
Sensorimotor Training and Gait in Diabetic Polyneuropathy
ClinicalTrials.gov study NCT04543032. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Neurotrophic Factors in Cerebrospinal Fluid in Diabetic Patients With Polyneuropathy
ClinicalTrials.gov study NCT01718015. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy
ClinicalTrials.gov study NCT04699734. IPD Sharing: NO. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.